ZEE5 Global, the world's largest streaming platform for South Asian content, announced the world digital premiere of its latest film, Hatyapuri. Starring popular actor Indraneil Sengupta as the famous sleuth Feluda, the upcoming mystery thriller is based on legendary filmmaker Satyajit Ray’s novel Hatyapuri. With the launch of this title, the platform further grows its crime and detective library which has been widely viewed and appreciated by consumers across the globe.
Directed and written by Sandip Ray, the high-octane mystery thriller also features Paran Banerjee, Sandip Chakraborty, and Debnath Chatterjee in pivotal roles. The edge-of-the-seat whodunnit will premiere on ZEE5 Global on 2nd June.
Hatyapuri Feluda follows Pradosh C. Mitter, aka Feluda, his nephew, Topshe, and close friend, Lalmohan Ganguly, on their vacation to the coastal city of Puri in Odisha. However, their plans change when the trio spots odd footprints on the sand one evening. Later, Lalmohan Babu goes to meet an astrologer who is presumably gifted with extrasensory perception to get more clarity. Things start getting bloody soon after they get involved in a murder in the city during their stay.
Archana Anand, Chief Business Officer, ZEE5 Global said, “At ZEE5 Global, we believe in offering our viewers varied and thought-provoking storylines by continually amping our libraries across 18 languages. Our Bengali library, one of the highest consumed globally, has been offering viewers new and compelling stories across genres and formats told by master storytellers. With the world digital premiere of our upcoming release Hatyapuri, we further amplify our offering with an all-new crime drama based on legendary filmmaker Satyajit Ray’s novel. The Bengali mystery thriller promises adventure, mystery, and drama as it follows popular sleuth Feluda on a new adventure.”
Director Sandip Ray said, “ I have always been inspired by my father’s literary creations, and over the years I have been keen to introduce them to viewers in newer forms and formats. Hatyapuri has been a personal favourite and I knew that this was a story that had to find a way to the audiences and I am glad that OTT has given me this opportunity. This gripping thriller will keep you on the edge of your seat as the characters keep surprising you for more. Excited to collaborate with ZEE5 Global to take this exciting adventure of Feluda to our global viewers.”
Actor Indraneil Sengupta said, “Nothing excites me more than playing Feluda in Satyajit Ray’s universe! Sandip sir has brought out the character in a very nuanced way, and I had to ensure I do justice to him. Feluda is an iconic character and I hope the viewers like our approach and freshness towards this story.”
Viewers can catch ZEE5 Global's unmissable slate of 111 titles and stock up on their yearlong entertainment by subscribing to the Annual pack and grabbing the limited-time special offer price.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.